Immunosuppressive drugs committee minutes, Oslo, Norway, 25 September 2023
Room C (11:30)

Attending:
Satohiro Masuda (chair), Florian Lemaitre (vice-chair), Teun van Gelder, Tomasz Pawinski, Maria Shipkova, Christoph Seger, Judith Taibon, Eberhard Wieland, Uwe Christians, Stein Bergan, Roland Lawson, Natalia Riva, Brenda de Winter, Laure Elens, Nuria Lloberas, Pierre Marquet, Olga Millan, Pawel Kunicki, Mercè Brunet, Smitta Pattanaik, Jana Stojanova (new member), Soufian Meziyerh (new member), Naoki Yoshikawa (new member)

Satohiro Masuda presents the agenda of the committee. Due to the physical absence of members like the meeting in 2022 at Prague, no formal vote on discussed points was organized during the meeting with the exception of election of the chair and vice-chair. Final approval of the points discussed will be sent by e-mail to everyone for their comments.

The ISD committee received application of Jana Stojanova, Soufian Meziyerh, Naoki Yoshikawa and Christine Staatz for joining the committee.

Annual general meeting
The annual general meeting has been sent to everyone for validation before being made available on the IATDMCT website.

Election of the Chair and Vice-Chair of the ISD committee
Satohiro Masuda’s term as the committee chair has come to an end and according the standard process of the committee, the vice-chair becomes the new chair of the committee. Florian Lemaitre becomes now the ISD committee chair. Nuria Lloberas was elected as the new vice-chair by acclamation.

Everolimus consensus document
Final modifications collected immediately before the OSLO meeting. Loralie Langman, who could not attend the business meeting, and Florian Lemaitre worked on the manuscript and proposed to reduce the volume of manuscript of the chapters with too much spaces and of the sentences especially that the information was almost not updated.
During the meeting, Uwe Christians, Maria Shipkova, Teun van Gelder, Smita Pattanaik, Eberhard Wieland and Stein Bergan gave comments for this topic.
According to the policy at beginning the collection of manuscript,
#1 about 3 to 4 pages for each chapter,
#2 each manuscript should be limited to be an updated topic of the document in comparison with the previous version of 2016,
#3 basically duplications except for sentences that cannot be deleted such as basic pharmacology of EVR should be avoided in new version.
The decision is to make the final version circulate within the group of authors for them to check whether their part can be read as a standalone, without getting back to the 2016
consensus document. If yes, the objective of updating is achieved. If no, the leader section should modify the document within two weeks from now (November the 8th).

**ISD SC webpage**

A new website will be launched refreshing and updating is required. It will be up to the chair and vice-chair to ensure the ISD SC page update.

**New Projects**

**CyA consensus document**: Because more than 20 years unfold from the consensus in the field, consensus documents on cyclosporine should be handled. Prof Uwe Christians agrees to lead the initiative, which will start as soon as the work on the everolimus consensus document will end.

**Bridge clinical society**: To enhance the impact of IATDMCT on clinical practice, a bridge between the association and clinical societies can be built. This would be relevant to reach out to the AST (American Society of Transplantation) and/or the ESOT (European Society of Organ Transplantation) to probe their feeling toward TDM practices and try to disseminate our knowledge to academic societies outside of IATDMCT. Florian will contact them and propose a common initiative on the “ideal” practice guidelines to personalized ISD therapy in solid organ transplant recipients. Pavel Kunicki added that organizing a joint session dedicated to TDM/ISD personalization would be a relevant initiative.

**Education**: Discussion on an educative document on TDM and personalization of ISD therapy has been made in the past. Our Dutch colleagues lead an initiative on notebook that can be translated in English and could help as the starting point for this project. Not so much progress on this initiative to date.

**ISD Symposium in Banff**: Starting from January, the Banff LOC will ask our ISD SC to propose a tentative agenda for the ISD symposium during the annual meeting. Members can make proposals by keeping in mind that to the best of possibility, we are asking to promote diversity, which means: providing speakers from 3 different continents, having a balance diversity regarding male and female speakers and at least one young scientist.

**TDM special issue**: On a side note, *Therapeutic Drug Monitoring* will be published a special issue on TDM and proposals are welcome.